gtd
DESCRIPTION
TRANSCRIPT
![Page 1: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/1.jpg)
Gestational trophoblastic disease Gestational trophoblastic disease (GTD)(GTD)
Gestational trophoblastic disease Gestational trophoblastic disease (GTD)(GTD)
![Page 2: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/2.jpg)
Gestational trophoblastic disease (GTD)Gestational trophoblastic disease (GTD)
Group of diseasesGroup of diseases
Abnormal proliferation of trophoblastic Abnormal proliferation of trophoblastic cellscells
Following an antecedent pregnancyFollowing an antecedent pregnancy
![Page 3: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/3.jpg)
Gestational trophoblastic disease (GTD)Gestational trophoblastic disease (GTD)
Molar pregnanciesMolar pregnancies
Invasive molesInvasive moles
Gestational choriocarcinomasGestational choriocarcinomas
Placental-site trophoblastic tumorsPlacental-site trophoblastic tumors
![Page 4: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/4.jpg)
Molar pregnanciesMolar pregnanciesComplete moleComplete mole
Partial molePartial mole
![Page 5: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/5.jpg)
Comparison of partial & complete moleComparison of partial & complete mole
CharacteristicsCharacteristics Complete moleComplete mole Partial molePartial mole
CytogeneticsCytogenetics 46,xx 46,xx (parternal)(parternal)
69,xxx triploid69,xxx triploid(2 parternal)(2 parternal)
pathologypathology Diffuse hydropic villi and Diffuse hydropic villi and trophoblastic proliferation trophoblastic proliferation
fetal absentfetal absent
Focal hydropic villi and Focal hydropic villi and trophoblastic proliferation trophoblastic proliferation fetal or fetal RBC presentfetal or fetal RBC present
ClinicalClinical USG Dx, large uterus, USG Dx, large uterus, thecalutein cysts, thecalutein cysts, pre-eclamsia, etcpre-eclamsia, etc
Abortion like, Abortion like, others rareothers rare
Malignant Malignant sequelaesequelae
20%20% < 5%< 5%
![Page 6: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/6.jpg)
IncidenceIncidence
Rare diseaseRare disease
between 0.2-9.9 : 1000 pregnancies.between 0.2-9.9 : 1000 pregnancies.
Asia is 10 times higher than Europe and Asia is 10 times higher than Europe and North America.North America.
about 1.87:1000 pregnancies in Vajira about 1.87:1000 pregnancies in Vajira Hospital.Hospital.
![Page 7: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/7.jpg)
Risk factorsRisk factors
AgeAge
Socioeconomic statusSocioeconomic status
Reproductive history (abortion, infertile)Reproductive history (abortion, infertile)
Race/ethnicRace/ethnic
Diet (carotene, fat)Diet (carotene, fat)
Previous molar pregnancyPrevious molar pregnancy
![Page 8: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/8.jpg)
Signs & SymptomsSigns & Symptoms
PregnancyPregnancy
11stst Vaginal bleeding (97%) Vaginal bleeding (97%)
Passage of hydropic villi.Passage of hydropic villi.
Anemia Anemia
Excessive uterine size.Excessive uterine size.
Medical condition: Pre-eclampsia, Hyper-emesis Medical condition: Pre-eclampsia, Hyper-emesis hyperthyroidism, Resp. insufficiency.hyperthyroidism, Resp. insufficiency.
Present of theca lutein cyst.Present of theca lutein cyst.
![Page 9: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/9.jpg)
DiagnosisDiagnosis
USGUSG– vesicular sonographic pattern, vesicular sonographic pattern,
(snow storm).(snow storm).
– Focal cystic change in placenta.Focal cystic change in placenta.
– A ratio of transverse and A-P A ratio of transverse and A-P dimension >1.5.dimension >1.5.
hCGhCG– Markedly elevated (>100,000 Markedly elevated (>100,000
mIU/ml in 40%).mIU/ml in 40%).
![Page 10: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/10.jpg)
Differential DiagnosisDifferential Diagnosis
Abortion with hydropic degenerationAbortion with hydropic degeneration
Missed abortionMissed abortion
Incomplete abortionIncomplete abortion
Pregnancy with other complication: twins, Pregnancy with other complication: twins, wrong date, other ovarian tumor, etc.wrong date, other ovarian tumor, etc.
ChoriocarcinomaChoriocarcinoma
![Page 11: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/11.jpg)
ManagementManagement
Evaluation & StabilizationEvaluation & Stabilization
Evacuation Evacuation
Follow up and Close monitoring of hCGFollow up and Close monitoring of hCG
![Page 12: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/12.jpg)
Evaluation & StabilizationEvaluation & Stabilization
Complete history and physical examination.Complete history and physical examination.
Investigation:Investigation:– hCG, CBC, BUN, Cr, LFT, thyroid function hCG, CBC, BUN, Cr, LFT, thyroid function
tests tests – pelvic USG, CXRpelvic USG, CXR
Stabilized hemodynamic and complication.Stabilized hemodynamic and complication.
![Page 13: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/13.jpg)
EvacuationEvacuation
Suction curettageSuction curettage
Dilatation & curettage (D/C)Dilatation & curettage (D/C)
HysterotomyHysterotomy
HysterectomyHysterectomy
![Page 14: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/14.jpg)
ComplicationComplication
Theca lutein cysts: pain, torsion, rupture, Theca lutein cysts: pain, torsion, rupture, bleeding.bleeding.
Respiratory distress syndrome.Respiratory distress syndrome.
Hyperthyroidism.Hyperthyroidism.
Uterine perforation.Uterine perforation.
![Page 15: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/15.jpg)
Follow upFollow up
Clinical-physical examination.Clinical-physical examination.
Serum hCGSerum hCG– 24-48 hr. after evacuation24-48 hr. after evacuation– q 1 wk. until normal for 3 times.q 1 wk. until normal for 3 times.– q 1 mo. until 6-12 mo.q 1 mo. until 6-12 mo.
Other investigations as indicated.Other investigations as indicated.
Contraception 6-12 mos. (OC, condom).Contraception 6-12 mos. (OC, condom).
![Page 16: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/16.jpg)
Risk factors for GTTRisk factors for GTT
Age > 40 yrs.Age > 40 yrs.
Pre-evacuation hCG > 100,000 mIU/ml.Pre-evacuation hCG > 100,000 mIU/ml.
Uterine size greater than GA.Uterine size greater than GA.
Theca lutein cysts > 6 cm. or bilateral cysts.Theca lutein cysts > 6 cm. or bilateral cysts.
Medical complication.Medical complication.
RDS post evacuation.RDS post evacuation.
![Page 17: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/17.jpg)
Subsequence pregnancySubsequence pregnancy
Recurrent rate 1-2% (15-30% after 2Recurrent rate 1-2% (15-30% after 2ndnd mole) mole)
Not increase in adverse pregnancy outcome.Not increase in adverse pregnancy outcome.
Recommend early ANC and 1Recommend early ANC and 1stst USG. USG.
Send placenta or conceptive products for Send placenta or conceptive products for histology.histology.
hCG 6 week post-partum.hCG 6 week post-partum.
![Page 18: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/18.jpg)
Gestational trophoblastic neoplasia (GTN)Gestational trophoblastic neoplasia (GTN)
Synonyms: gestational trophoblastic Synonyms: gestational trophoblastic tumor (GTT), malignant GTD, persistent GTD, tumor (GTT), malignant GTD, persistent GTD, etc. etc.
Include invasive mole, choriocarcinoma, placental Include invasive mole, choriocarcinoma, placental site trophoblastic tumor.site trophoblastic tumor.
Histologic present is invasive trophoblastic Histologic present is invasive trophoblastic proliferation with or without villi.proliferation with or without villi.
Histologic Diagnosis is not necessary before Rx.Histologic Diagnosis is not necessary before Rx.
45% present with metastatic disease.45% present with metastatic disease.
![Page 19: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/19.jpg)
Hormonal criteriaHormonal criteria
Four values or more of plateaued hCG Four values or more of plateaued hCG ((± 10%) over at least 3 wks.± 10%) over at least 3 wks.
Rising of hCG > 10% for 3 Values or more Rising of hCG > 10% for 3 Values or more over at least 2 wks.over at least 2 wks.
The histologic diagnosis of choriocarcinoma.The histologic diagnosis of choriocarcinoma.
Persistence of hCG beyond 6 mos. or more.Persistence of hCG beyond 6 mos. or more.
![Page 20: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/20.jpg)
Pre-therapy evaluationPre-therapy evaluation
Assessment of clinical risk factors.Assessment of clinical risk factors.
Physical examination include PVPhysical examination include PV
Laboratory evaluation: hematologic Laboratory evaluation: hematologic test, basic chemistry test, hCGtest, basic chemistry test, hCG
Radiographic survey: CXR or CT Radiographic survey: CXR or CT chest, USG or CT Abdomen, chest, USG or CT Abdomen, CT or MRI brain.CT or MRI brain.
![Page 21: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/21.jpg)
Clinical risk fartorsClinical risk fartors
AgeAge
Type of antecedent pregnancy Type of antecedent pregnancy
Interval from antecedent pregnancyInterval from antecedent pregnancy
Previous treatmentPrevious treatment
![Page 22: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/22.jpg)
Common metastatic sitesCommon metastatic sites
Lung 80%Lung 80%
Vagina 30%Vagina 30%
Liver 10%Liver 10%
Brain 10%Brain 10%
Other : GI, kidney, Other : GI, kidney, lymph node, etc.lymph node, etc.
* Liver and brain metastasis are rarely if no lung or * Liver and brain metastasis are rarely if no lung or vaginal metastasis.*vaginal metastasis.*
![Page 23: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/23.jpg)
FIGO stage (2000)FIGO stage (2000)
II Disease confined to the uterus.Disease confined to the uterus.
IIII Disease extend outside uterus, but limited to genital Disease extend outside uterus, but limited to genital structures.structures.
IIIIII Disease extend to lung with or without genital tract Disease extend to lung with or without genital tract involvement.involvement.
IVIV All other metastatic sites.All other metastatic sites.
Anatomical stage
![Page 24: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/24.jpg)
FIGO stage (2000)FIGO stage (2000)Risk score (modified WHO)
scorescore 00 11 22 44Age (yrs)Age (yrs) <40<40 ≥≥4040 -- --
Antecedent pregnancyAntecedent pregnancy MoleMole AbortionAbortion TermTerm
Interval from index preg. Interval from index preg. (mos)(mos)
<4<4 4-<74-<7 7-<137-<13 ≥≥1313
Pre-treatment hCG (IU/l)Pre-treatment hCG (IU/l) <10<1033 101033-<10-<1044 101044-<10-<1055 ≥≥101055
Largest tumor size (cm)Largest tumor size (cm) <3<3 3-<53-<5 ≥≥55 --
Site of metastasisSite of metastasis LungLung Spleen, Spleen, kidneykidney
Gastro-Gastro-intestinalintestinal
Liver, Liver, brainbrain
Number of metastasisNumber of metastasis -- 1-41-4 5-85-8 >8>8
Previous failed chemotherapyPrevious failed chemotherapy -- -- SingleSingle Two or Two or moremore
![Page 25: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/25.jpg)
FIGO stage (2000)FIGO stage (2000)
Write stage:score such as Write stage:score such as stage II:4, stage IV:9stage II:4, stage IV:9
Minimum score = 0, maximum score = 25Minimum score = 0, maximum score = 25
Low risk group score < 7 Low risk group score < 7 High risk group score ≥ 7High risk group score ≥ 7
![Page 26: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/26.jpg)
Clinical classification for GTNClinical classification for GTN
Non-metastatic GTNNon-metastatic GTN
Metastatic GTNMetastatic GTN– Good prognosisGood prognosis– Poor prognosisPoor prognosis
![Page 27: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/27.jpg)
Prognosis for metastatic GTNPrognosis for metastatic GTN
Good prognosis Good prognosis
Duration < 4 mos.Duration < 4 mos.
hCG < 40,000 mIU/mlhCG < 40,000 mIU/ml
No antecedent term preg.No antecedent term preg.
No brain or liver metastasis. No brain or liver metastasis.
No prior chemotherapy. No prior chemotherapy.
Poor prognosisPoor prognosis
Duration ≥ 4 mos.Duration ≥ 4 mos.
hCG ≥ 40,000 mIU/ml.hCG ≥ 40,000 mIU/ml.
Antecedent term preg.Antecedent term preg.
Brain or liver metastasis.Brain or liver metastasis.
Prior chemotherapy.Prior chemotherapy.
![Page 28: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/28.jpg)
Management of GTNManagement of GTNManagement of GTNManagement of GTN
![Page 29: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/29.jpg)
Low risk GTNLow risk GTN
Single agent chemotherapy most common Single agent chemotherapy most common MTX, actinomycin D. MTX, actinomycin D.
Hysterectomy if complete family.Hysterectomy if complete family.
One additional dose after negative hCG.One additional dose after negative hCG.
Resistant to one drug can shift to another Resistant to one drug can shift to another single agent.single agent.
2.5-4% recurrence, mostly in 18 mos.2.5-4% recurrence, mostly in 18 mos.
![Page 30: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/30.jpg)
Single drug regimenSingle drug regimen
Drug Dose Duration(days)
MTX - 1 mg/kg day 1,3,5,7 with folinic acid 0.1 mg/kg day 2,4,6,8
- 20-25 mg (0.4 mg/kg) IM x 5 days
14
7-14
Actinomycin D -10 µg/kg IV x 5 days
-1.25 mg/m2 IV
14
5 FU 30 mg/kg/d continuous 10 30 mg/kg/d continuous 10 day infusion day infusion
-
Etoposide 200 mg/m200 mg/m22 oral x 5 days oral x 5 days 14
![Page 31: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/31.jpg)
Criteria for drug resistanceCriteria for drug resistance
hCG plateaus with three weekly hCG plateaus with three weekly measurements.measurements.
hCG rising ≥ 10% in two consecutive hCG rising ≥ 10% in two consecutive measurements.measurements.
Evidence of new metastasis.Evidence of new metastasis.
![Page 32: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/32.jpg)
High risk GTNHigh risk GTN
5 yrs. survival nearly 90%.5 yrs. survival nearly 90%.
Initial treatment is multi-drug regimen: Initial treatment is multi-drug regimen: EMA-CO, MAC, MAC III, CHAMOCA EMA-CO, MAC, MAC III, CHAMOCA
Treatment continued 2-3 cycle after Treatment continued 2-3 cycle after negative hCG for 3 wks.negative hCG for 3 wks.
Radiotherapy for brain or liver metastasis.Radiotherapy for brain or liver metastasis.
![Page 33: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/33.jpg)
High risk GTNHigh risk GTN
Surgical resection if indicated (single lesion, Surgical resection if indicated (single lesion, resistant nodule).resistant nodule).
Salvage therapy: EMA-EP, ICE, BEP.Salvage therapy: EMA-EP, ICE, BEP.
Common causes of death are hemorrhage Common causes of death are hemorrhage and pulmonary insufficiency.and pulmonary insufficiency.
![Page 34: Gtd](https://reader036.vdocuments.us/reader036/viewer/2022062617/54c8c9214a7959573c8b456f/html5/thumbnails/34.jpg)
Follow up for GTNFollow up for GTN
Clinical evaluation.Clinical evaluation.
hCG measurementhCG measurement– weekly until normal x 3 wks.weekly until normal x 3 wks.
– Monthly until normal x 12-24 mos.Monthly until normal x 12-24 mos.
Investigation as indicated.Investigation as indicated.
Contraception if remain fertility.Contraception if remain fertility.